Sight Sciences (SGHT)
(Delayed Data from NSDQ)
$3.49 USD
+0.02 (0.58%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.48 -0.01 (-0.29%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SGHT 3.49 +0.02(0.58%)
Will SGHT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGHT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGHT
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
SGHT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates
Artivion (AORT) Lags Q1 Earnings Estimates
Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics
Other News for SGHT
Sight Sciences (SGHT) Reveals Cost-Efficient TearCare System for Eye Disease
Sight Sciences announces results of CUA assessing TearCare system
Sight Sciences announces publication of 24-month results of SAHARA RCT
Sight Sciences (SGHT) Publishes Promising 24-Month Results from SAHARA Trial